Interestingly, we observed no significant difference in expression of the immune checkpoint programmed cell death protein-1 (PD-1), while CDNP-R848-treatment led to a substantial decline of lymphocyte activating 3 (Lag3) expression in both CD4 and CD8 T cells during the tumor clearing phase (Fig. 3g). This evidence concerns the gene LAG3 and neoplasm.